The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis.

Autor: Chiaravalloti ND; Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ, 07936, USA. nchiaravalloti@kesslerfoundation.org.; Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School, Newark, NJ, USA. nchiaravalloti@kesslerfoundation.org., Amato MP; Department NEUROFARBA, Section Neurosciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Brichetto G; Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), via Operai 40, 16149, Genoa, Italy.; AISM Rehabilitation Service, Italian Multiple Sclerosis Society, Genoa, Italy., Chataway J; Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, Queen Square Multiple Sclerosis Centre, University College London, London, WC1B 5EH, UK.; National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK., Dalgas U; Exercise Biology, Department of Public Health, Aarhus University, Dalgas Avenue 4, 8000, Aarhus, Denmark., DeLuca J; Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ, 07936, USA.; Department of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School, Newark, NJ, USA., Meza C; Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, ON, M5R 3B6, Canada., Moore NB; Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ, 07936, USA., Feys P; REVAL, Faculty of Rehabilitation Sciences, Hasselt University, Diepenbeek, Belgium., Filippi M; Division of Neuroscience, Neuroimaging Research Unit, Institute of Experimental Neurology, IRCSS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy.; Neurology Unit, IRCSS San Raffaele Scientific Institute, Milan, Italy.; Neurophysiology Unit, IRCSS San Raffaele Scientific Institute, Milan, Italy.; Vita-Salute San Raffaele University, Milan, Italy., Freeman J; Faculty of Health, School of Health Professions, University of Plymouth, Devon, UK., Inglese M; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, and Center of Excellence for Biomedical Research, University of Genoa, Genoa, Italy.; Ospedale Policlinico San Martino-IRCCS, Genoa, Italy., Motl R; Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, USA., Rocca MA; Division of Neuroscience, Neuroimaging Research Unit, Institute of Experimental Neurology, IRCSS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy.; Neurology Unit, IRCSS San Raffaele Scientific Institute, Milan, Italy., Sandroff BM; Kessler Foundation, 120 Eagle Rock Avenue, Suite 100, East Hanover, NJ, 07936, USA.; Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, USA., Salter A; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA., Cutter G; Department of Biostatistics, University of Alabama At Birmingham, Birmingham, USA., Feinstein A; Department of Psychiatry, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, ON, M5R 3B6, Canada.
Jazyk: angličtina
Zdroj: Journal of neurology [J Neurol] 2021 May; Vol. 268 (5), pp. 1598-1607. Date of Electronic Publication: 2020 Aug 19.
DOI: 10.1007/s00415-020-10160-7
Abstrakt: Objective: Individuals with pre-existing chronic illness have shown increased anxiety and depression due to COVID-19. Here, we examine the impact of the COVID-19 pandemic on emotional symptomatology and quality of life in individuals with Progressive Multiple Sclerosis (PMS).
Methods: Data were obtained during a randomized clinical trial on rehabilitation taking place at 11 centers in North America and Europe. Participants included 131 individuals with PMS. Study procedures were interrupted in accordance with governmental restrictions as COVID-19 spread. During study closure, a COVID Impact Survey was administered via telephone or email to all participants, along with measures of depressive symptoms, anxiety symptoms, quality of life, and MS symptomatology that were previously administered pre-pandemic.
Results: 4% of respondents reported COVID-19 infection. No significant changes were noted in anxiety, quality of life, or the impact of MS symptomatology on daily life from baseline to lockdown. While total HADS-depression scores increased significantly at follow-up, this did not translate into more participants scoring above the HADS threshold for clinically significant depression. No significant relationships were noted between disease duration, processing speed ability or EDSS, and changes in symptoms of depression or anxiety. Most participants reported the impact of the virus on their psychological well-being, with a little impact on financial well-being. The perceived impact of the pandemic on physical and psychological well-being was correlated with the impact of MS symptomatology on daily life, as well as changes in depression.
Conclusions: Overall, little change was noted in symptoms of depression or anxiety or overall quality of life.
Databáze: MEDLINE
Externí odkaz: